Interpace Diagnostics, BCBS form clinical agreement

Interpace Diagnostics, a diagnostic testing and pathology services provider, agreed to participate in the Blue Cross Blue Shield Association’s Center for Clinical Effectiveness program “Evidence Street.”

Advertisement

Under the agreement, Interpace Diagnostics’ thyroid and pancreas tests will be covered by BCBS’ 36 independent companies across the U.S.

“We are excited about our evolving relationship with Blue Cross and Blue Shield’s Evidence Street which, we believe, will help ensure that we continue to develop and provide the information and data necessary to support and secure broader based insurance coverage and reimbursement for all of our products,” said Jack Stover, president and CEO of Interpace Diagnostics.

More articles on payer issues: 

BCBS, Texas Health Resources settle contract dispute
CBO blog offers guidance on ACA replacement proposals for refundable tax credits
How the ‘big 5’ payers performed financially in 2016

Advertisement

Next Up in Uncategorized

  • Health systems are navigating a rapidly evolving healthcare environment where patient safety is shaped by both longstanding challenges and emerging…

  • Since 2020, CHS has announced or completed the sale of 35 hospitals:  2025 2024 2023 2022 2021 In July 2021,…

  • Sacroiliac joint fusion technology is advancing, and the data shows it’s efficacy across different medtech companies. Five notes: 1. Tenon…

Advertisement

Comments are closed.